Description du projet
Un remède contre les complications neurologiques de la COVID-19
L’impact des fréquentes complications neurologiques et psychiatriques résultant de l’infection par le SARS-CoV-2 peut être dévastateur à l’échelle d’une pandémie en raison de l’absence de traitement. Le projet NEUROCOV, financé par l’UE, étudiera donc les complications cognitives et neurodégénératives associées à la COVID-19, la neuro-COVID, en utilisant une approche interdisciplinaire innovante. L’objectif est de développer une méthodologie visant à anticiper et à gérer les vulnérabilités personnalisées et leurs impacts au niveau de la population. L’approche générale fera appel à l’épidémiologie, à la recherche sur l’interaction hôte/virus au niveau de la cellule unique et à la modélisation prédictive pour identifier des biomarqueurs et des médicaments potentiels à réadapter. Le spectre phénotypique de la neuro-COVID sera obtenu grâce aux principaux registres de santé nationaux et à trois cohortes cliniques, ce qui permettra d’analyser les complications, les facteurs de risque et le fardeau socio-économique.
Objectif
The COVID19 pandemic has shown our health care fragility vis a vis novel pathogens, with a global disruption on societal welfare. Despite the towering success of vaccine development, lack of preparedness on integrative clinical and molecular phenotyping has emerged with clarity and highlights the need to scale translational efforts for personalized prevention and therapy. Of particular concern are the long-term consequences of SARS-CoV-2 infection with high and rising prevalence of chronic manifestations referred to as Post-COVID. Among these the neurological and psychiatric complications stand out for frequency, lack of treatment and devastating impact of their effects at pandemic scale. Here, we tackle the cognitive and neurodegenerative complications of COVID-19, referred to as NeuroCOVID, as a ticking pandemic within the pandemic that requires an innovation leap across disciplines. We pursue a multi scalar approach that reaches from epidemiology and mechanistic interrogation of host/virus interplay at single cell resolution through predictive modelling all the way to validation of biomarkers and repurposed drugs. The aim is to anticipate and effectively manage personalized trajectories of NeuroCOVID vulnerability and their impact at population level. For this we leverage two leading national health registries and three clinical cohorts to characterize the phenotypic spectrum of NeuroCOVID, its risk factors and its socioeconomic burden at high definition. We pioneer innovative robotics to scale brain organoid modelling and combine it with single cell multiOMICs and AI analytics to dissect the principles of the individual host response and render experimentally actionable the authentic genetic backgrounds of differential SARS-CoV-2 sensitivity. Through a substantive engagement of patients’ collectives and health care stakeholders, upstream integration of innovative pipelines streamlines translation and operationalizes precision medicine for emerging medical needs.
Champ scientifique
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health scienceshealth sciencespublic healthepidemiologypandemics
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health scienceshealth sciencespersonalized medicine
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringrobotics
Mots‑clés
Programme(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
53127 Bonn
Allemagne